Valuation: Medivir AB

Market Cap 1B 101M 88.68M 83.76M 76.33M 143M 9.69B 144M 388M 4.95B 379M 371M 15.9B P/E 2026 *
-10.6x
P/E 2027 * -7.42x
Enterprise Value 906M 91.38M 80.19M 75.74M 69.02M 129M 8.76B 130M 351M 4.47B 343M 336M 14.38B EV / Sales 2026 *
197x
EV / Sales 2027 * 5.77x
Free-Float
63.91%
Yield 2026 *
-
Yield 2027 * -
1 day-2.83%
1 week-5.21%
Current month-20.54%
1 month+2.15%
3 months+10.73%
6 months-38.86%
Current year+264.12%
1 week 0.11
Extreme 0.1076
0.13
1 month 0.11
Extreme 0.1076
0.16
Current year 0
Extreme 0.0001
0.26
1 year 0
Extreme 0.0001
0.26
3 years 0
Extreme 0.0001
0.69
5 years 0
Extreme 0.0001
1.11
10 years 0
Extreme 0.0001
9.39
Manager TitleAgeSince
Chief Executive Officer 55 24/01/2022
Director of Finance/CFO - 23/03/2026
Chief Tech/Sci/R&D Officer 60 20/02/2023
Director TitleAgeSince
Chairman 76 05/05/2021
Director/Board Member 70 03/05/2018
Director/Board Member 47 05/05/2021
Change 5-day change 1-year change 3-year change Capi.($)
-2.83%-5.21% - - 101M
-3.30%+1.50%+51.24%+99.26% 72.26B
+1.25%-3.01%+40.12%+77.12% 60.24B
+2.12%+5.26%+32.50%+21.28% 27.73B
-3.06%-1.81%-13.10%+357.06% 25.74B
-0.75%+2.56%+0.45%-4.46% 24.75B
+0.40%+0.75%+22.91%-9.68% 20.74B
-1.70%-2.12%+146.86%+314.52% 15.06B
+0.36%-0.34%+50.32%+166.42% 14.42B
+0.21%+1.17%-8.07%+499.10% 14.23B
Average -0.73%+0.44%+35.92%+168.96% 30.57B
Weighted average by Cap. -0.77%+0.31%+36.31%+129.11%

Financials

2026 *2027 *
Net sales 4.6M 464K 407K 384K 350K 656K 44.46M 660K 1.78M 22.71M 1.74M 1.7M 72.99M 148M 14.97M 13.14M 12.41M 11.31M 21.17M 1.44B 21.32M 57.52M 733M 56.22M 55M 2.36B
Net income -72.78M -7.34M -6.44M -6.08M -5.54M -10.37M -703M -10.45M -28.19M -359M -27.55M -26.96M -1.15B 33.53M 3.38M 2.97M 2.8M 2.55M 4.78M 324M 4.81M 12.99M 166M 12.69M 12.42M 532M
Net Debt -96M -9.68M -8.49M -8.02M -7.31M -13.69M -928M -13.78M -37.18M -474M -36.34M -35.56M -1.52B -145M -14.62M -12.83M -12.12M -11.04M -20.67M -1.4B -20.82M -56.16M -716M -54.89M -53.71M -2.3B
Logo Medivir AB
Medivir AB is a Sweden-based pharmaceutical research and development company with focus on oncology. The Company specializes in protease inhibitor design and nucleoside and nucleotide science, applying it to development of therapies for cancers with unmet medical need. The Company's clinical pipeline consists of remetinostat, a topical histone deacetylase (HDAC) inhibitor in phase II of clinical studies for the treatment of cutaneous T-cell lymphoma (CTCL), birinapant in combination with Keytruda (pembrolizumab) in phase I of clinical studies for the treatment of solid tumors, MIV-818, a nucleotide-based prodrug in phase I of clinical trials for the treatment of liver cancer, and MIV-711, a cathepsin K (CTSK) inhibitor in IIa extension study for the treatment of osteoarthritis. Furthermore, the Company has additional research projects in cooperation with other institutions.
Employees
6
Date Price Change
25/09/26 €0.1238 -2.83%
24/09/26 €0.1274 -0.31%
23/09/26 €0.1278 -1.84%
22/09/26 €0.1302 +0.93%
21/09/26 €0.1290 -1.23%
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
CCC
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
1.622SEK
Average target price
5.768SEK
Spread / Average Target
+255.64%

Quarterly revenue - Rate of surprise